Email Updates

Search form

You are here

AVAC in the News

  • Researchers, clinicians, and advocates converging in Paris for the International AIDS Conference 2017 will not only be talking about new HIV treatment and prevention and how to roll out innovative medications in a comprehensive, integrated way, they will also be making a case to funders...."If funders feel the progress we're making, it will create dividends in more ways than one," said International AIDS Society President Linda-Gail Bekker. "We may see some threatened cuts put on hold."

    July 19, 2017
    Medscape
  • The surprise approval of generic Truvada (tenofovir disoproxil fumarate and emtricitabine) by the US Food and Drug Administration (FDA) on June 9 left patients, advocates and doctors scrambling to understand exactly when the generic will become available and how much it will cost.

    July 6, 2017
    The Body
  • Mitchell Warren calls, on National HIV Testing Day, for individuals to get tested, know their status and take appropriate steps to access treatment and prevention. And also for funders and policymakers to support life-saving and cost-saving testing programs that are the cornerstone of a comprehensive, integrated and sustained response to HIV.

    June 27, 2017
    TheBody.com
  • The US Food and Drug Administration (FDA) has approved the first generic version of emtricitabine/tenofovir disoproxil (Truvada, Gilead Sciences) to both treat and prevent HIV infections in this country, the agency announced today.

    June 9, 2017
    Medscape
  • Medical and health advocacy groups have come out largely in opposition to the Trump administration's proposed cuts in the 2018 budget, with one executive calling it a "disaster" to federal programs and institutions that provide resources to improve health.

    May 24, 2017
    Healthcare Finance
  • Activist Micheal Ighodaro speaks about being violently attacked in his home city, seeking asylum in the US and the issues that LGBT people across the world.

    May 23, 2017
    General
    Independent
  • The hard truth is we will pass many more May 18ths before we can celebrate a licensed accessible HIV vaccine. And HIV vaccine research can only succeed with enduring advocacy and fresh voices taking up the charge. That means the next generation of vaccine champions will need to rise to the challenge of keeping the hope for and need for an HIV vaccine in the forefront of HIV advocacy.

    May 18, 2017
    The Huffington Post
  • Gradually ramping up promotion of its HIV-prevention pill, Gilead Sciences has turned to humor, dating apps and social media sites like Tumblr and Snapchat to raise awareness about HIV prevention.

    May 3, 2017
    MM&M
  • The World Health Organization's reclassification last month of progestogen-only injectable contraceptives has triggered a critical debate in the family planning community over how to manage the potential link between higher rates of HIV acquisition and one of the most popular birth control methods in many at-risk communities.

    April 4, 2017
    Devex
  • A vaccine for HIV has been sought since the early days of the epidemic. After years of difficulties and setbacks, several new approaches are providing cause for optimism.

    April 1, 2017
    Lancet

Pages